Homepage
Author:
Trevi Therapeutics, Inc.
Posted Date:
April 1, 2026
Trevi Therapeutics to Participate in Upcoming Events
Trevi Therapeutics, Inc.
April 1, 2026
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
Trevi Therapeutics, Inc.
March 17, 2026
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
Trevi Therapeutics, Inc.
March 10, 2026
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
Trevi Therapeutics, Inc.
March 9, 2026
Trevi Therapeutics to Participate in Upcoming March Conferences
Trevi Therapeutics, Inc.
March 2, 2026
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Trevi Therapeutics, Inc.
February 17, 2026
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
Trevi Therapeutics, Inc.
January 27, 2026
